Abstract
While the majority of patients benefit from front-line therapies for diabetes and dyslipidemia, others present with diminished responses. These differences in drug efficacy appear to be due, in large part, to genetic polymorphisms affecting pharmacokinetics and drug-target interactions. Many studies have been conducted in an attempt to elucidate the pharmacogenetic relationship between a wide range of polymorphisms and their effects on responsiveness to statins, hypoglycemics, insulin sensitizers, antihypertensives and antioxidants. Regarding most polymorphisms, the results of association studies have not been validated consistently across different population groups. This review will present some of these pharmacogenetic relationships, focusing on the haptoglobin polymorphism and the responsiveness to vitamin E supplementation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
